Noninvasive monitoring of patients with chronic hepatitis C

摘要: Hepatic fibrosis is the main determinant of clinical outcomes chronic hepatitis C. Liver histology frequently considered gold standard for assessing hepatic fibrosis. However, liver biopsy associated with sampling error, interobserver variability, and potential complications. Thus, there a need simple, inexpensive, reliable noninvasive means to assess disease severity in patients Clinical examination unreliable differentiating different stages compensated disease. Among routine laboratory tests, decreased platelet count, increase ratio aspartate alanine aminotransferase (AST/ALT), prolonged prothrombin time are earliest indicators cirrhosis portal hypertension. Individual serum markers have limited accuracy predicting Indices composed panel correlate better histological fibrosis, but their reliability requires further validation. Currently, monitoring C relies on evaluation, ultrasound endoscopic surveillance cirrhosis. Initial evaluation should focus assessment activity stage prognostication decisions regarding treatment, rule out coinfections other causes Subsequent follow-up detection progression treatment. The frequency tests used will depend patient's age, disease, comorbid conditions. There an urgent develop validate that can accurately reflect full spectrum inflammation